TrialPloS one2015

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.

Antonia Lepida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.